Hot Investor Mandate 1: Asia Evergreen Fund Seeks Medtech and Biotech with Proof of Concept Data

29 Dec

A healthcare-focused US$100 million evergreen fund based in Taipei, Taiwan seeks to participate in Series A to C rounds and is open to leading or following. Typical investments range from US$0.5 to 2 million, while larger investments can be considered on a case-by-case basis. The firm expects to make 4-5 new deals in the coming 12 months. The firm is currently seeking opportunities from Taiwan, the US, and Canada.

Within healthcare, the firm considers broadly across the healthcare field, including biomedicine, medical devices, diagnostics, and healthcare IT. When it comes to overseas deals, the firm prefers products that have achieved prototype and clinical proof-of-concept. The firm is opportunistic in terms of disease areas.

The firm is looking for competent and experienced management teams. The firm does not require board representation after investment. As a financially-driven investor, the firm does not typically request regional rights, but it can provide assistance with finding local partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: